The survival rate of biological therapy in immunosuppressive diseases in children
Authors:
- Татьяна Вячеславовна РадыгинаТРТатьяна Вячеславовна Радыгина
- Светлана Валентиновна ПетричукСПСветлана Валентиновна Петричук
- Андрей Петрович ФисенкоАФАндрей Петрович Фисенко
- Darya G. KuptsovaDKDarya G. Kuptsova
- Ольга Владимировна КурбатоваОКОльга Владимировна Курбатова
- Луизат Муслимовна АбдуллаеваЛАЛуизат Муслимовна Абдуллаева
- Ekaterina V. FreydlinEFEkaterina V. Freydlin
- Александр Сергеевич ПотаповАПАлександр Сергеевич Потапов
- Николай Николаевич МурашкинНМНиколай Николаевич Мурашкин
- Людмила Михайловна КузенковаЛКЛюдмила Михайловна Кузенкова
- Елена Леонидовна СемикинаЕСЕлена Леонидовна Семикина
Open Access
- 12 November 2024
- journal article
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 27 (5) , 322-330
Abstract
Genetically engineered biological preparations (GEBP) are successfully used in various immunosuppressive diseases. Despite the effectiveness of GEBP, some patients experience primary non-response, as well as loss of effect from therapy. There is a need to objectively assess the effect of the therapy for its timely correction. The aim of the work was to determine the survival rate of GIBP depending on the form of pathology, drug, age, and immune indices in children with Crohn’s disease (CD), ulcerative colitis (UC), psoriasis (PS), multiple sclerosis (MS). Materials and methods. Three hundred eighty three children (1394 observations) were examined in dynamics: 117 children with BC (treated by infliximab (IFX)/adalimumab (ADA), 83 children with UC (IFX/ADA), 87 children with PS (ADA), 96 children with PC (IFNβ1α) during the maintenance course therapy. Lymphocytes were immunophenotyped by flow cytometry with the determination of Treg (CD4+CD25highCD127low), Th17 lymphocytes (CD4+CD161+CD3+), succinate dehydrogenase (SDH) activity in Treg. Data processing was carried out using Statistica 16.0 application. Kaplan–Mayer survival curves are constructed. The significance of the differences between the groups was assessed using the Gehan–Wilcoxon criterion (p < 0.05). Results. The survival rate of biological therapy in CD patients on IFX therapy is significantly higher than in children with UC — 161 weeks versus 135 weeks. There was no difference in CBT on ADA therapy between patients with CD and UC. The IBT index depends on the age of the patients: on IFX therapy (159 weeks) the best indices were in CD patients over 12 years. Combination therapy improves the survival of TNF blockers in patients with IBD (azathioprine) and PS (methotrexate). The survival of GIBP is influenced by the ratio of effector and regulatory cells (Th17|Treg) and the functional activity of Treg (SDH activity). A decrease in IBD was revealed in patients with IBD, PS, and MS with an increase in the Th17/Treg index above the age norm and a decrease in the activity of SDH in Treg below the norm. Conclusion. The survival rate of biological therapy for immunosuppressive diseases in children depends on the form of pathology, the drug, the age of patients, previous therapy, combination therapy, as well as immune indices during the maintenance course. Monitoring of Th17/Treg and SDH activity in Treg may be an important laboratory criterion for the effectiveness of GIBP.Keywords
This publication has 27 references indexed in Scilit:
- The Immunology of Psoriasis—Current Concepts in PathogenesisClinical Reviews in Allergy & Immunology, 2024
- Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort studyThe Lancet Gastroenterology & Hepatology, 2024
- Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResourceJournal of Crohn's and Colitis, 2023
- Combination therapy in inflammatory bowel disease: Current evidence and perspectivesInternational Immunopharmacology, 2022
- The influence of cytokines on the complex pathology of ulcerative colitisAutoimmunity Reviews, 2022
- The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline UpdateJournal of Crohn's and Colitis, 2020
- Imbalance between T helper 17 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosisBiomedicine & Pharmacotherapy, 2018
- Multiple Sclerosis: Mechanisms and ImmunotherapyNeuron, 2018
- Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledgeExpert Review of Clinical Immunology, 2018
- Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failedAlimentary Pharmacology & Therapeutics, 2015